AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 37864252
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (traditional post-stroke rehabilitation program without VR therapy)
Trial: 37864281
Drug: Lisinopril (0.05
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lisinopril (0.05 to 0.2 mg/kg, oral, once daily in the morning)
Trial: 37864379
Drug: insulin glargine
RxNorm normalized name: Insulin Glargine
DrugBank: Insulin glargine (DB00047)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: insulin glargine (IGlar)
Trial: 37864379
Drug: beinaglutide combined
RxNorm normalized name: Liraglutide
DrugBank: Liraglutide (DB06655)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: beinaglutide combined with insulin glargine (IGlar)
Trial: 37864583
Drug: Nutritional stabilization
RxNorm normalized name: Ocean Blue Nutritionals Omega-3 1450 Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nutritional stabilization and medical treatment during hospitalization (mean hospitalization: 6 weeks)
Trial: 37864596
Drug: Lifestyle therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lifestyle therapy (Control)
Trial: 37864646
Drug: PT2385 (800
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PT2385 (800 mg b.i.d.)
Trial: 37864885
Drug: 4-(3-1H-indazolyl)amino quinazoline
RxNorm normalized name: 4-amino-PGA
DrugBank: Aminopterin (DB08878)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4-(3-1H-indazolyl)amino quinazoline derivatives (compounds 27e, 27g, 27i, and 27j)
Trial: 37865043
Drug: 5 μg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 μg vaccine
Trial: 37865043
Drug: 15 μg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 15 μg vaccine
Trial: 37865043
Drug: 45 μg
RxNorm normalized name: tazarotene
DrugBank: Tazarotene (DB00799)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 45 μg vaccine
Trial: 37865043
Drug: One 45
RxNorm normalized name: idebenone 45 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: One 45 μg dose of vaccine followed by placebo (Part 1 only)
Trial: 37865048
Drug: Nimotuzumab (NTZ)
DrugBank: Nimotuzumab (DB06192)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nimotuzumab (NTZ) combined with concurrent chemoradiotherapy (CCRT)
Trial: 37865138
Drug: Extended-release naltrexone
RxNorm normalized name: bupropion / naltrexone Extended Release Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Extended-release naltrexone (XR-NTX) 380 mg/month
Trial: 37865138
Drug: Buprenorphine-naloxone (BP-NLX)
RxNorm normalized name: buprenorphine / naloxone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Buprenorphine-naloxone (BP-NLX) 8-24/2-6 mg daily
Trial: 37865397
Drug: Durvalumab (1500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Durvalumab (1500 mg) and tremelimumab (75 mg) with neoadjuvant chemotherapy (NAC) for three cycles, followed by interval debulking surgery (IDS), then durvalumab (1120 mg) and adjuvant chemotherapy for three cycles, followed by durvalumab maintenance (1120 mg for total 12 cycles).
Trial: 37865397
Drug: Neoadjuvant chemotherapy
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neoadjuvant chemotherapy (NAC) combined with durvalumab and tremelimumab.
Trial: 37865397
Drug: Treatment-related adverse
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment-related adverse events (TRAEs) from durvalumab and tremelimumab.
Trial: 37865101
Drug: Empagliflozin 10
RxNorm normalized name: empagliflozin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Empagliflozin 10 mg once daily for 28 days
Trial: 37865736
Drug: Surf tablet
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Surf tablet usage
Trial: 37865736
Drug: Surf tablet
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Surf tablet usage among satisfied parents
Trial: 37865771
Drug: Pegunigalsidase alfa
RxNorm normalized name: Pegunigalsidase alfa
DrugBank: Pegunigalsidase alfa (DB14992)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pegunigalsidase alfa (1 mg/kg every 2 weeks)
Trial: 37865771
Drug: Agalsidase alfa
RxNorm normalized name: Agalsidase alfa
DrugBank: Agalsidase alfa (DB15874)
FDA approved: no
EMA approved: yes
PMDA approved: no
Description: Agalsidase alfa (0.2 mg/kg every 2 weeks)
Trial: 37865776
Drug: Pre-ICI collections
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pre-ICI collections from patients with irAEs G ≥ 2
Trial: 37865776
Drug: Post-treatment collections
RxNorm normalized name: hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Post-treatment collections from subjects experiencing irAEs G ≥ 2
Trial: 37865776
Drug: Post-treatment collections
RxNorm normalized name: hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Post-treatment collections after steroids
Trial: 37865807
Drug: COMORAL (multi-channeled
FDA approved: no
EMA approved: no
PMDA approved: no
Description: COMORAL (multi-channeled oral irrigation unit) used 3 times a day, 5 days a week
Trial: 37865807
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (no supplementary oral hygiene products, brushing 1-2 times a day)
Trial: 37865807
Drug: COMORAL (multi-channeled
FDA approved: no
EMA approved: no
PMDA approved: no
Description: COMORAL (multi-channeled oral irrigation unit)
Trial: 37865896
Drug: Lazertinib (240
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lazertinib (240 mg/d)
Trial: 37866442
Drug: Cycle of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cycle of trauma and drug use exacerbated by oppression in substance use services settings
Trial: 37866460
Drug: Remibrutinib 100
RxNorm normalized name: Ibrutinib
DrugBank: Ibrutinib (DB09053)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Remibrutinib 100 mg twice daily for 52 weeks
Trial: 37866669
Drug: Autologous hematopoietic
RxNorm normalized name: Autologous Hematopoietic Peripheral Blood Stem Cells
DrugBank: Autologous Hematopoietic Peripheral Blood Stem Cells (DB17067)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Autologous hematopoietic stem cell transplantation (aHSCT) with cyclophosphamide 200 mg/Kg and rituximab 1000 mg
Trial: 37867420
Drug: Perampanel 4
RxNorm normalized name: perampanel 4 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Perampanel 4 mg/day
Trial: 37868294
Drug: Lacalut cleaning
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lacalut cleaning tablet
Trial: 37868294
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of brushing and Lacalut cleaning tablet
Trial: 37868649
Drug: Acthar Gel
RxNorm normalized name: Acthar Gel
DrugBank: Corticotropin (DB01285)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Acthar Gel
Trial: 38416237
Drug: Faricimab treatment
RxNorm normalized name: Faricimab
DrugBank: Faricimab (DB15303)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Faricimab treatment
Trial: 37868959
Drug: Plasma biomarkers
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Plasma biomarkers (endothelin-1, von Willebrand factor, Interleukin-1 Receptor antagonist)
Trial: 37869085
Drug: Regorafenib (80
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Regorafenib (80 mg once daily on days 1-21 of each 28 days cycle) + Toripalimab (240 mg, q3w) + High-dose radiotherapy (4-8 fractions of 8-12Gy) and Low-dose radiotherapy (1-10Gy at 0.5-2Gy/fraction)
Trial: 37869085
Drug: Regorafenib (120
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Regorafenib (120 mg once daily on days 1-21 of each 28 days cycle)
Trial: 37869360
Drug: Rilzabrutinib 400
RxNorm normalized name: Rilzabrutinib
DrugBank: Rilzabrutinib (DB17709)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rilzabrutinib 400 mg BID
Trial: 37870130
Drug: Oral antibiotics
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral antibiotics (various types including penicillins, cephalosporins, macrolides, and trimethoprim) for 10-14 days
Trial: 37870163
Drug: SB16 (60
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SB16 (60 mg dose)
Trial: 37870163
Drug: EU-DEN (60
FDA approved: no
EMA approved: no
PMDA approved: no
Description: EU-DEN (60 mg dose)
Trial: 37870163
Drug: US-DEN (60
FDA approved: no
EMA approved: no
PMDA approved: no
Description: US-DEN (60 mg dose)
Trial: 37870228
Drug: PB-IORT (Precision
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PB-IORT (Precision breast intraoperative radiation therapy) with customized CT-based HDR brachytherapy delivering 12.5 Gy to the tumor bed.
Trial: 37870228
Drug: PB-IORT (Precision
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PB-IORT (Precision breast intraoperative radiation therapy) with customized CT-based HDR brachytherapy.
Trial: 37870510
Drug: Nonhormonal selective
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nonhormonal selective NK3R antagonist
Trial: 39261417
Drug: Trastuzumab deruxtecan
RxNorm normalized name: Trastuzumab deruxtecan
DrugBank: Trastuzumab deruxtecan (DB14962)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Trastuzumab deruxtecan (T-DXd) 5.4 mg/kg once every 3 weeks
Trial: 37870862
Drug: Topiramate (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topiramate (100 mg per day maximum-tolerated dose)
Trial: 37870954
Drug: Oral tamoxifen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral tamoxifen citrate, 20 mg/d
Trial: 37870954
Drug: 4-hydroxytamoxifen gel,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4-hydroxytamoxifen gel, 2 mg/d per breast
Trial: 37870955
Drug: Control (investigator's
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (investigator's choice of therapy with pembrolizumab, ipilimumab, or dacarbazine)
Trial: 37870968
Drug: 960-mg sotorasib-panitumumab
RxNorm normalized name: SOTORASIB
DrugBank: Sotorasib (DB15569)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 960-mg sotorasib-panitumumab
Trial: 37870968
Drug: 240-mg sotorasib-panitumumab
RxNorm normalized name: sotorasib 240 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 240-mg sotorasib-panitumumab
Trial: 37870973
Drug: Control treatment
RxNorm normalized name: SALICYLIC ACID 190 mg in 1 mL TOPICAL LIQUID [Derma E Acne Blemish Control Treatment Serum]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control treatment (platinum-based chemotherapy with or without pembrolizumab)
Trial: 37870976
Drug: Amivantamab-chemotherapy
RxNorm normalized name: amivantamab
DrugBank: Amivantamab (DB16695)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Amivantamab-chemotherapy
Trial: 37871309
Drug: Enasidenib (ENA)
DrugBank: Enasidenib (DB13874)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Enasidenib (ENA) monotherapy
Trial: 37871555
Drug: Dual therapy
RxNorm normalized name: Tums Dual Action
DrugBank: Alginic acid (DB13518)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dual therapy (DT) with dolutegravir or darunavir/cobicistat plus lamivudine
Trial: 37871555
Drug: Triple therapy
RxNorm normalized name: MigreLief Triple Therapy with Puracol Caplet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Triple therapy (TT) with integrase inhibitors
Trial: 37871576
Drug: Giroctocogene fitelparvovec
RxNorm normalized name: Giroctocogene fitelparvovec
DrugBank: Giroctocogene fitelparvovec (DB16174)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Giroctocogene fitelparvovec gene therapy (3 × 10^13 vg/kg)
Trial: 37871576
Drug: Giroctocogene fitelparvovec
RxNorm normalized name: Giroctocogene fitelparvovec
DrugBank: Giroctocogene fitelparvovec (DB16174)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Giroctocogene fitelparvovec gene therapy
Trial: 37871604
Drug: Pembrolizumab 200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pembrolizumab 200 mg combined with trastuzumab plus fluoropyrimidine and platinum-based chemotherapy
Trial: 37871604
Drug: Placebo combined
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo combined with trastuzumab plus fluoropyrimidine and platinum-based chemotherapy
Trial: 37871608
Drug: Atezolizumab plus
RxNorm normalized name: Atezolizumab
DrugBank: Atezolizumab (DB11595)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Atezolizumab plus bevacizumab (1200 mg atezolizumab plus 15 mg/kg bevacizumab every 3 weeks for 17 cycles)
Trial: 37871703
Drug: Sacituzumab govitecan
RxNorm normalized name: sacituzumab govitecan
DrugBank: Sacituzumab govitecan (DB12893)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Sacituzumab govitecan (SG) + Enfortumab vedotin (EV) administered on days 1 + 8 of a 21-day cycle until progression or unacceptable toxicity.
Trial: 37871703
Drug: Sacituzumab govitecan
RxNorm normalized name: sacituzumab govitecan
DrugBank: Sacituzumab govitecan (DB12893)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Sacituzumab govitecan (SG) 8 mg/kg with Enfortumab vedotin (EV) 1.25 mg/kg with granulocyte colony-stimulating factor support; MTDs are SG 10 mg/kg with EV 1.25 mg/kg.
Trial: 37871841
Drug: No Margin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No Margin Treatment (Control)
Trial: 37872020
Drug: Toripalimab plus
RxNorm normalized name: Toripalimab
DrugBank: Toripalimab (DB15043)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Toripalimab plus axitinib (240 mg intravenously once every 3 weeks + 5 mg orally twice daily)
Trial: 37872020
Drug: Sunitinib (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sunitinib (50 mg orally once daily for 4 weeks or 2 weeks)
Trial: 37872225
Drug: Higher dose
RxNorm normalized name: BENZOCAINE 50 mg in 1 mL TOPICAL GEL [HIGHER CONTROL Male Climax Control Lubricating]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Higher dose level (DL) treatment
Trial: 37872639
Drug: Adolescent survey
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adolescent survey on discussions about safe use of pain medications
Trial: 37873555
Drug: Enpatoran 50
RxNorm normalized name: Enpatoran
DrugBank: Enpatoran (DB16501)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enpatoran 50 mg
Trial: 37873555
Drug: Enpatoran 100
RxNorm normalized name: Enpatoran
DrugBank: Enpatoran (DB16501)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enpatoran 100 mg
Trial: 37873786
Drug: Oncolytic reovirus
RxNorm normalized name: Reovirus type 3 dearing oncolytic virus without transgenes
DrugBank: Pelareorep (DB17284)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oncolytic reovirus treatment administered for 5 days every 28 days.
Trial: 37873863
Drug: MEDI7247 (pyrrolobenzodiazepine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MEDI7247 (pyrrolobenzodiazepine antibody-drug conjugate)
Trial: 37874619
Drug: Self-administered on
RxNorm normalized name: Gel-One
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Self-administered on the tablet app using a chatbot interface
Trial: 37874619
Drug: Administered by
RxNorm normalized name: COVID-19 testing administered by pharmacist
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered by an in-person clinician
Trial: 37874619
Drug: Administered by
RxNorm normalized name: COVID-19 testing administered by pharmacist
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered by a telehealth clinician
Trial: 37874908
Drug: TAVR +
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TAVR + medical therapy
Trial: 37874913
Drug: Immunochemotherapy (mostly
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immunochemotherapy (mostly R-CHOP 75% and reduced dose R-CHOP 13%)
Trial: 37875144
Drug: Neoadjuvant cemiplimab
RxNorm normalized name: cemiplimab
DrugBank: Cemiplimab (DB14707)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Neoadjuvant cemiplimab 350 mg intravenously every 3 weeks followed by curative-intent surgery
Trial: 37875323
Drug: Zimberelimab (240
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Zimberelimab (240 mg every 2 weeks for 2 years)
Trial: 37875559
Drug: Probiotic compound
RxNorm normalized name: Rezyst Probiotic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Probiotic compound AB001 at single dose
Trial: 37875559
Drug: Probiotic compound
RxNorm normalized name: Rezyst Probiotic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Probiotic compound AB001 at double dose
Trial: 37875578
Drug: zuranolone 50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: zuranolone 50 mg co-initiated with standard-of-care antidepressant therapy (ADT)
Trial: 37875578
Drug: placebo co-initiated
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo co-initiated with standard-of-care antidepressant therapy (ADT)
Trial: 37875637
Drug: Chewable beetroot-based
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chewable beetroot-based supplement (BR-CT)
Trial: 37875771
Drug: Alpelisib in
RxNorm normalized name: Product containing alpelisib in oral dose form (medicinal product form)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alpelisib in combination with cetuximab
Trial: 37875771
Drug: Alpelisib-cetuximab combination
RxNorm normalized name: Cetuximab
DrugBank: Cetuximab (DB00002)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Alpelisib-cetuximab combination
Trial: 37875792
Drug: Intermediate dose
RxNorm normalized name: Prevotella intermedia
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intermediate dose enoxaparin (60 mg for 45-60 kg, 80 mg for 61-100 kg, 100 mg for >100 kg) once daily for 14 days, with dose adjustment according to anti-factor Xa activity.
Trial: 37875792
Drug: Intermediate dose
RxNorm normalized name: Prevotella intermedia
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intermediate dose enoxaparin (IC)
Trial: 37875792
Drug: Observational cohort
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Observational cohort (OC) receiving enoxaparin 40 mg/day
Trial: 37875813
Drug: Oral microbiota
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral microbiota model for SAP patients
Trial: 37875856
Drug: Tango-therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tango-therapy
Trial: 37875869
Drug: PIPAC with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PIPAC with cisplatin (10.5 mg/m2 in 150 mL NaCl 0.9%) and doxorubicin (2.1 mg/m2 in 50 mL NaCl 0.9%) followed by 2 cycles of FOLFOX every 6-7 weeks (total of 3 PIPACs and 6 cycles of FOLFOX).
Trial: 37875943
Drug: VHW-led, CDSS-assisted
FDA approved: no
EMA approved: no
PMDA approved: no
Description: VHW-led, CDSS-assisted T2D care model including lifestyle counselling, first-line oral antidiabetic, lipid-lowering, and antiplatelet treatment guided by a tablet-based CDSS.
Trial: 37875997
Drug: Conbercept intravitreal
RxNorm normalized name: Dexamethasone Intravitreal Implant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conbercept intravitreal injection (IVC)
Trial: 37876018
Drug: HoNOS-13 questionnaire
RxNorm normalized name: Hongo Killer
DrugBank: Undecylenic acid (DB11117)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: HoNOS-13 questionnaire (13-item version including medication compliance)
Trial: 37876046
Drug: Damoctocog alfa
RxNorm normalized name: DAMOCTOCOG ALFA PEGOL
DrugBank: Damoctocog alfa pegol (DB14700)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Damoctocog alfa pegol (prophylaxis every 3-4 days, median infusion dose of 37.5 IU/kg)
Trial: 37876540
Drug: Pasireotide monotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pasireotide monotherapy
Trial: 37876540
Drug: Pasireotide monotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pasireotide monotherapy and combination therapy
Trial: 37876886
Drug: Acacia 5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acacia 5 g daily
Trial: 37876886
Drug: Acacia 10
RxNorm normalized name: ACACIA 1000 [PNU] in 1 mL INTRADERMAL INJECTION, SOLUTION [ACACIA]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acacia 10 g daily
Trial: 37876886
Drug: Microcrystalline cellulose
RxNorm normalized name: Microcrystalline Cellulose
DrugBank: Microcrystalline cellulose (DB14158)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Microcrystalline cellulose (MCC) 10 g daily
Trial: 37876886
Drug: All dietary
RxNorm normalized name: All Clear
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: All dietary treatment arms (Acacia 5 g/d, Acacia 10 g/d, MCC)
Trial: 37876998
Drug: Ultra-low-dose CT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ultra-low-dose CT (ULDCT)
Trial: 37877219
Drug: Third dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Third dose of ZF2001 after 3-4 months
Trial: 37877219
Drug: Third dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Third dose of ZF2001 after 5-6 months
Trial: 37877219
Drug: Third dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Third dose of ZF2001 after 7-9 months
Trial: 37877260
Drug: N-acetylcysteine (NAC)
DrugBank: Acetylcysteine (DB06151)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: N-acetylcysteine (NAC) 150 mg/kg
Trial: 38907342
Drug: Selumetinib treatment
RxNorm normalized name: selumetinib
DrugBank: Selumetinib (DB11689)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Selumetinib treatment
Trial: 37878295
Drug: Percutaneous coronary
RxNorm normalized name: Glebionis coronaria whole extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Percutaneous coronary intervention (PCI) in addition to optimal medical therapy
Trial: 37878624
Drug: G-CSF +
RxNorm normalized name: G-CSF
DrugBank: Lenograstim (DB13144)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: G-CSF + Plerixafor
Trial: 37878675
Drug: PRGN-2012 treatment
RxNorm normalized name: benzoyl peroxide
DrugBank: Benzoyl peroxide (DB09096)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: PRGN-2012 treatment at the highest dose
Trial: 37878675
Drug: PRGN-2012 treatment
RxNorm normalized name: benzoyl peroxide
DrugBank: Benzoyl peroxide (DB09096)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: PRGN-2012 treatment
Trial: 37878786
Drug: Ticagrelor monotherapy
RxNorm normalized name: Ticagrelor
DrugBank: Ticagrelor (DB08816)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ticagrelor monotherapy (90 mg twice daily) after <1 month of DAPT (n=1426)